Stapled transperineal repair for low- and mid-level rectovaginal fistulas: A 5-year experience and comparison with sutured repair

BACKGROUNDCurrently, rectovaginal fistula (RVF) continues to be a surgical challenge worldwide, with a relatively low healing rate. Unclosed intermittent suture and poor suture materials may be the main reasons for this.AIMTo evaluate the efficacy and safety of stapled transperineal repair in treating RVF.METHODSThis was a retrospective cohort study conducted in the Coloproctology Department of The Sixth Affiliated Hospital of Sun Yat-sen University (Guangzhou, China). Adult patients presenting with RVF who were surgically managed by perineal repair between May 2015 and May 2020 were included. Among the 82 total patients, 37 underwent repair with direct suturing and 45 underwent repair with stapling. Patient demographic data, Wexner faecal incontinence score, and operative data were analyzed. Recurrence rate and associated risk factors were assessed.RESULTSThe direct suture and stapled repair groups showed similar clinical characteristics for aetiology, surgical history, fistula features, and perioperative Wexner score. The stapled repair group did not show superior results over the suture repair group in regard to operative time, blood loss, and hospital stay. However, the stapled repair group showed better postoperative Wexner score (1.04 ± 1.89 vs 2.73 ± 3.75, P = 0.021), less intercourse pain (1/45 vs 17/37, P = 0.045), and lower recurrence rate (6/45 vs 17/37, P = 0.001). There was no protective effect from previous repair history, smaller diameter of fistula (< 0.5 cm), better control of defecation (Wexner < 10), or stapled repair. Direct suture repair and preoperative high Wexner score (> 10) were risk factors for fistula recurrence. Furthermore, stapled repair gave better efficacy in treating complex RVFs (i.e., multiple transperineal repair history, mid-level fistula position, and poor control of defecation).CONCLUSIONStapled transperineal repair is advantageous for management of RVF, providing a high primary healing rate and low recurrence rate.     

三七粉质量标志物研究＊

三七为常用中药材，具有散瘀、止血，消肿定痛的功效。三七粉作为三七市场应用的主要形式之一，市场逐年增大。现行标准难以评价和控制三七粉“多重功效”的质量特点。本课题组在系统辨识三七粉化学物质组及其传递规律的基础上，采用网络药理学和体内、体外模型，研究并阐明了三七粉的活血、心肌与血管保护、止血以及消肿定痛的药效物质基础；进一步结合成分的特有性分析，确定了三七粉的质量标志物；在此基础上，建立了基于质量标志物的三七粉的指纹图谱及“一测多评”的多指标含量测定方法，为建立三七粉整体质量控制方法提供了理论与实验证据。     

First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric,gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis

First-line chemotherapy for advanced/metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric/gastroesophageal junction cancer (GC/GEJC) has poor median overall survival (OS; <1 year). We report efficacy and safety results from Chinese patients in the phase III global CheckMate 649 study of nivolumab plus chemotherapy vs chemotherapy for the first-line treatment of GC/GEJC/esophageal adenocarcinoma (EAC). Chinese patients with previously untreated advanced or metastatic GC/GEJC/EAC were randomized to receive nivolumab (360 mg Q3W or 240 mg Q2W) plus chemotherapy (XELOX [capecitabine and oxaliplatin] Q3W or FOLFOX [oxaliplatin, leucovorin and 5-fluorouracil] Q2W), nivolumab plus ipilimumab (not reported) or chemotherapy alone. OS, blinded independent central review-assessed progression-free survival (PFS), objective response rate (ORR), duration of response (DOR) and safety are reported. Of 1581 patients enrolled and randomized, 208 were Chinese. In these patients, nivolumab plus chemotherapy resulted in clinically meaningful improvement in median OS (14.3 vs 10.2 months; HR 0.61 [95% CI: 0.44-0.85]), median PFS (8.3 vs 5.6 months; HR 0.57 [95% CI: 0.40-0.80]), ORR (66% vs 45%) and median DOR (12.2 vs 5.6 months) vs chemotherapy, respectively. The safety profile was acceptable, with no new safety signals observed. Consistent with results from the global primary analysis of CheckMate 649, nivolumab plus chemotherapy demonstrated a clinically meaningful improvement in OS and PFS and higher response rate vs chemotherapy and an acceptable safety profile in Chinese patients. Nivolumab plus chemotherapy represents a new standard first-line treatment for Chinese patients with non-HER2-positive advanced GC/GEJC/EAC.     

进食障碍患者家庭顺应量表的汉化及信效度检验

目的 汉化进食障碍患者家庭顺应量表，并检验其信效度。方法 根据Brislin翻译模式将量表翻译成中文，通过专家函询和预调查对量表进行文化调适和修订。将量表应用于300例进食障碍患者照顾者检验信效度。结果 中文版进食障碍患者家庭顺应量表的量表水平内容效度指数为0.918。探索性因子分析结果显示5个因子可解释总变异量的49.862%。量表的各维度得分与量表总分呈中高度相关，各维度得分之间呈中低度相关或不相关。量表总Cronbach′s α为0.877，重测信度为0.883。结论 中文版进食障碍患者家庭顺应量表具有较好的信效度，可用于测量进食障碍患者的家庭顺应情况。     

S100蛋白水平联合Rotterdam-CT评分、GCS评分在TBI病情和预后不良评估中的价值

目的 探讨S100蛋白(S100 protein,S100)水平联合Rotterdam计算机X线断层扫描(Computed tomography,CT)评分、格拉斯哥昏迷评分(Glasgow coma scale,GCS)在创伤性颅脑损伤(Traumatic brain injury,TBI)病情和预后不良评估中的价值。方法 回顾性分析106例TBI患者的临床资料,比较不同病情TBI患者血清S100水平、Rotterdam-CT评分,分析血清S100水平与Rotterdam-CT评分、GCS评分的相关性; 根据患者预后情况分为预后良好组和预后不良组,比较2组性别、年龄、血清S100水平、Rotterdam-CT评分、GCS评分等临床资料,多因素logistic回归分析TBI患者预后不良的相关因素; 分析S100蛋白水平、GCS评分、Rotterdam-CT评分及三者联合应用对TBI患者预后不良的预测价值。结果 轻度组、中度组、重度组血清S100水平、Rotterdam-CT评分逐渐增高(P<0.01),TBI患者血清S100水平与GCS评分(r=0.396,P=0.001)、Rotterdam-CT评分(r=0.289,P=0.002)均呈正相关; 2组血氧饱和度、GCS评分、呼吸频率、Rotterdam-CT评分、S100蛋白水平、入院时昏迷占比等指标有明显差异(P<0.05或P<0.01); 多因素logistic回归分析显示呼吸频率、血氧饱和度、入院时昏迷占比、GCS评分、Rotterdam-CT评分、S100蛋白水平均为TBI患者预后不良的相关危险因素; 受试者工作特征曲线(Receiver operator characteristic curve,ROC)显示S100蛋白水平、GCS评分、Rotterdam-CT评分对TBI患者预后不良均有一定的预测价值,三项指标联合应用曲线下面积(Area of the under curve,AUC)值大于各单项指标预测。结论 S100蛋白水平、GCS评分、Rotterdam-CT评分是TBI患者预后不良的相关危险因素,S100蛋白水平联合GCS评分、Rotterdam-CT评分在TBI患者预后不良评估中具有较高的临床价值。